Immune checkpoint inhibitors in advanced nonsmall cell lung cancerHelissey, Carole; Champiat, Stephane; Soria, Jean-CharlesCurrent Opinion in Oncology: March 2015 - Volume 27 - Issue 2 - p 108–117 doi: 10.1097/CCO.0000000000000167 LUNG AND MEDIASTINUM: Edited by Robert Pirker Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Targeting immune checkpoints has led to promising results in metastatic nonsmall cell lung cancer (NSCLC). By restoring antitumor immunity, these treatments are able to induce prolonged clinical responses. The level of activity and the durability of responses observed in phase I trials has led most companies to launch phases II and III trials whose results are highly expected. Recent findings In this review, we present efficacy and toxicity results of the different immune checkpoint inhibitors (ICIs) currently developed in NSCLC and report other checkpoints currently explored. The specific profile of tumor responses and immune-related toxicity observed with immunotherapy will be addressed. Finally, to illustrate the new insights into the development of these drugs, we will give an overview of the different ICIs combination studies evaluated in NSCLC and will discuss the role of programmed cell death-L1 as a potential biomarker. Summary This review will address some of the future challenges of ICIs in NSCLC. Department of Drug Development and South Paris University, Gustave Roussy Cancer Campus, Villejuif, France Correspondence to Professor Jean-Charles Soria, MD, PhD, Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif 94805, France. E-mail: firstname.lastname@example.org Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.